Starpharma Presents at Macquarie Investor Event
Starpharma is one of two healthcare companies presenting at the Macquarie Bank Australia and New Zealand Annual Corporate Day in Hong Kong and Singapore.
Commencing today, the presentation to institutional investors from the Asia region will include 33 companies from Australia, from either the top 50 or 200 ASX listed companies.
Annual Report and Full Year Financial Results
Starpharma today released its annual report and financial results for the year ended 30 June 2011.
Financial Results
- Cash position at end of year $18.9M
- Net cash burn for the year $3.9M
- Cash outflows from operations $6.5M
- Reported loss $8.9M
GSK Awarded Funds to Advance Dermal Treatment with Starpharma's Dendrimers
GlaxoSmithKline (GSK), and Starpharma today announced that GSK was awarded a grant to advance a dermal treatment based on Starpharma’s dendrimer drug delivery technology.
The funds will be used to support Starpharma’s synthesis of dendrimer-based drug candidates which will then be tested by Stiefel, a GSK company with a view to further development towards a dermal product.
Starpharma terminates Reckitt Agreement and signs with Ansell
Starpharma today announced two important developments in relation to the commercialisation of its VivaGel®-coated condom.
Key Points:
- Starpharma terminates condom coating agreement with Reckitt Benckiser
- Starpharma executes condom coating agreement with Ansell
Starpharma Commences Bacterial Vaginosis Prevention Study of VivaGel®
Starpharma today announced the commencement of its Phase 2 study of VivaGel® for the prevention of bacterial vaginosis (BV), following receipt of ethics approval.